MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy

The MIB‐1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB‐1 labeling index at the time of diag...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Yamamoto, Eri, Tomita, Naoto, Sakata, Seiji, Tsuyama, Naoko, Takeuchi, Kengo, Nakajima, Yuki, Miyashita, Kazuho, Tachibana, Takayoshi, Takasaki, Hirotaka, Tanaka, Masatsugu, Hashimoto, Chizuko, Koharazawa, Hideyuki, Fujimaki, Katsumichi, Taguchi, Jun, Harano, Hiroshi, Motomura, Shigeki, Ishigatsubo, Yoshiaki
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2013
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653523/
https://ncbi.nlm.nih.gov/pubmed/24112697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12288
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia